GRWD5769 Shrinks Tumors in 26 of 83 Patients as ASCO Highlights New Cancer Drug Gains
Updated
Updated · The Guardian · Jun 6
GRWD5769 Shrinks Tumors in 26 of 83 Patients as ASCO Highlights New Cancer Drug Gains
3 articles · Updated · The Guardian · Jun 6
Summary
GRWD5769 helped shrink tumors in 26 of 83 heavily pretreated patients whose cancers had resisted or stopped responding to immunotherapy; 15 saw reductions of at least 30%.
The experimental tablet works by stripping tumor cells of an “invisibility cloak,” allowing the immunotherapy drug cemiplimab to recognize and attack cancers including cervical, bladder, liver, bowel, lung, and head and neck tumors.
ASCO also heard that daraxonrasib doubled average survival in 500 patients with metastatic pancreatic cancer to 13.2 months from about 6.6-6.7 months, while mezigdomide more than doubled progression-free survival in multiple myeloma.
Other studies suggested some patients may avoid harsher treatment: a 4,000-patient breast cancer trial found genomic testing could spare many women chemotherapy, and adding durvalumab helped some bladder cancer patients avoid surgery.
The upbeat drug data was tempered by setbacks and strain on care systems: Galleri missed its main endpoint in a 142,000-patient UK trial, and ASCO researchers warned annual cancer cases could rise from 20 million to 35.3 million by 2050.
With tests now sparing patients from chemo, is the future of cancer care more drugs or avoiding treatment altogether?
Will a global cancer workforce shortage make the latest drug breakthroughs inaccessible for most future patients?
If a pill can double pancreatic cancer survival, why did the 'holy grail' early detection blood test just fail its biggest trial?
EMITT-1 Trial at ASCO 2026: GRWD5769’s Novel Mechanism Boosts Immunotherapy Success in Resistant Tumors
Overview
At the 2026 ASCO annual meeting in Chicago, GRWD5769 stood out as a leading 'smart drug' among the conference's top breakthroughs. This innovative therapy was highlighted for its ability to overcome key limitations of current cancer treatments. While immunotherapy has changed cancer care by using the immune system to fight tumors, its effectiveness can drop when cancer cells hide from detection. GRWD5769 addresses this problem by making hidden cancer cells visible to the immune system, offering new hope for patients and marking a major step forward in oncology.